1. Cancer
  2. Cancer Metabolism and Metastasis

Cancer Metabolism and Metastasis

Metabolic abnormalities are a major feature of cancer, such as increased substance anabolic pathways and aerobic glycolysis. Cancer metabolism shows flexibility and plasticity, which are crucial for the survival and growth of cancer cells. Cancer metastasis is completed in five steps i.e. invasion, dissemination, circulating tumor cells, colonization, and secondary tumor formation. Recently, metabolic adaptation mechanism of cancer metastasis has been proposed to reveal the extensive relationship between cancer metabolism and cancer metastasis. Metastasizing cancer cells selectively and dynamically adapt their metabolism during the complex multistep cascade.

Many nutrients can promote metabolite plasticity during metastasis. For example, lactic acid and pyruvate are the nutrients that cells can directly absorb from the environment; many cancer cells take up glutamine, which contributes to non-essential amino acid as well as nucleotide synthesis through nitrogen or carbon metabolism. Inhibiting the function of key enzymes in metabolic pathways can in turn inhibit the proliferation of cancer cells. For example, lactate dehydrogenase A or B (LDH-A or -B) knockdown can inhibit breast cancer cell motility in vitro. Oncogenic signaling pathways, such as Myc, phosphoinositide 3-kinase (PI3K)/AKT pathway, MAPK/ERK pathway, LKB1/AMPK pathway and Hippo pathways, mediate metabolic gene expression and increase metabolic enzyme activities.

Cancer Metabolism and Metastasis Related Products (42796):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-U00279
    Nitracrine 4533-39-5
    Nitracrine inhibits RNA synthesis and covalently, reversibly binds to DNA but also forms covalent adducts with DNA in vivo. Nitracrine, a 1-nitroacridine derivative, is a potent hypoxia-selective agent in vitro and antitumor agent. Nitracrine has cytotoxicity towards most cells.
    Nitracrine
  • HY-U00358
    Compound 2 872313-42-3
    Compound 2 is an active compound used for the research of metabolic bone diseases.
    Compound 2
  • HY-N0624
    Complanatoside A 146501-37-3
    Complanatoside A is a flavonol glycoside isolated from Astragalus complanatus, and currently it is used as a quality control index for A. complanatus in the 2010 edition of the Chinese Pharmacopoeia.
    Complanatoside A
  • HY-P0301
    SLLK, Control Peptide for TSP1 Inhibitor 2918768-29-1
    SLLK, Control Peptide for TSP1 Inhibitor is a control peptide for LSKL (leucine-serine-lysine-leucine).
    SLLK, Control Peptide for TSP1 Inhibitor
  • HY-P0307
    Antennapedia Peptide 188842-14-0 98.35%
    Antennapedia Peptide (Penetratin peptide) is a 16 amino acid peptide, originally derived from the 60 amino acid long homeodomain of the Drosophila transcription factor Antennapedia and is a member of the family of cell-penetrating peptides.
    Antennapedia Peptide
  • HY-U00324
    p38 MAPK-IN-2 635725-16-5
    p38 MAPK-IN-2 is an inhibitor of p38 kinase.
    p38 MAPK-IN-2
  • HY-U00247
    MCI826 140646-80-6
    MCI826 is a P-glycoprotein (P-gp) antagonist.
    MCI826
  • HY-U00414
    Antitumor agent-4 115767-64-1
    Antitumor agent-4, a butenylphenyl phosphate derivative, is a agent for mammary cancer and anovulatory sterility.
    Antitumor agent-4
  • HY-U00321
    A2B receptor antagonist 1 531506-36-2
    A2B receptor antagonist 1 is a potent A2B adenosine receptor antagonist extracted from patent WO 2009157938 A1 EXAMPLE 9B.
    A2B receptor antagonist 1
  • HY-U00390
    JAK3-IN-7 1263774-57-7
    JAK3-IN-7 is a potent and selective JAK3 inhibitor extracted from patent WO2011013785A1, has an IC50 of <0.01 μM.
    JAK3-IN-7
  • HY-U00345
    CHK-IN-1 1278405-51-8
    CHK-IN-1 is an inhibitor of CHK1 and CHK2, with anti-proliferative activities.
    CHK-IN-1
  • HY-U00312
    MEK-IN-1 870600-45-6
    MEK-IN-1 is a MEK inhibitor extracted from patent WO2008076415A1.
    MEK-IN-1
  • HY-U00223
    WD2000-012547 283172-68-9
    WD2000-012547 is a selective poly(ADP-ribose)-polymerase (PARP-1) inhibitor with a pKi of 8.221.
    WD2000-012547
  • HY-U00130
    1-Acetyl-3-o-toluyl-5-fluorouracil 71861-76-2
    1-Acetyl-3-o-toluyl-5-fluorouracil is a potent antitumor agent and a 5-fluorouracil analog.
    1-Acetyl-3-o-toluyl-5-fluorouracil
  • HY-U00088
    3β,7β,17β-Trihydroxyandrost-5-ene 2697-85-0
    3b,7a,17a-Trihydroxyandrost-5-ene is a immune modulator extracted from patent US20030060425.
    3β,7β,17β-Trihydroxyandrost-5-ene
  • HY-U00379
    LM985 87626-56-0
    LM985 is one of a series of compounds based on the flavone ring structure, with anti-tumor activities.
    LM985